Steve Bernstein
Analyst · the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this conference call. It is now my pleasure to introduce your host, Mr. Stanton Sloane, President and CEO
Thank you, Stan, and good afternoon. For the three months ended July 31, 2020, consolidated revenue was $13 million, up 3% compared to $12.6 million for the same period of the prior fiscal year. The components of revenue are as follows: revenue from commercial and U.S. government satellite programs was $6.7 million compared to $3.9 million for the same period of the prior fiscal year and accounted for approximately 51% of consolidated revenues compared to 31% for the same period of the prior fiscal year. Revenues on satellite payload contracts are recognized primarily under the percentage of completion method and are recorded only in the FEI-New York segment. Revenues from non-space U.S. Government and DOD customers, which are recorded in both the FEI-New York and FEI-Zyfer segments was $5.3 million compared to $6.7 million in the same period of the prior fiscal year and accounted for approximately 41% of consolidated revenue compared to 54% for the prior fiscal year. Other commercial and industrial revenues were $1 million compared to $1.9 million in the prior fiscal year. Intersegment revenues are eliminated in consolidation. For the three-month period ending July 31, 2020, the gross margin and gross margin rate both increased marginally over the same period in fiscal 2020. The increase is primarily due to product mix. There were higher engineering costs on several programs in both periods, but as these programs are completed, we expect margins to increase. For the three months ended July 31, 2020 and 2019, selling and administrative costs were approximately 25% and 20%, respectively of consolidated revenue. The increase is due to additional insurance costs and professional fees relating to litigation for which we expect to receive a partial reimbursement through the company's insurance. R&D expense for the three months ending July 31, 2020 and 2019 decreased to $1.2 million from $2.3 million, a decrease of $1.1 million and were 9% and 18% of consolidated revenue. The decrease is due to previous R&D efforts that have ended and turned into production. However, the company plans to continue to invest in R&D. For the three months ended July 31, 2020, the company recorded an operating loss of $337,000 compared to $780,000 in the prior year. The operating loss reflects improved in revenue, gross margin and gross margin rate. Other income consists primarily investment income derived from the company's holdings of marketable securities. The prior year investment income included a dividend received from Morion of $125,000. This yields a pretax loss of approximately $253,000 compared to a pretax loss of approximately $570,000 for the previous year. For the three months ending July 31, 2020, the company recorded a tax provision of $9,000 compared to $19,000 for the same period of fiscal 2020. Consolidated net loss for the three months ending July 31, 2020, was $262,000 or $0.03 per diluted share compared to $591,000 or $0.07 per diluted share in the previous year. Our fully funded backlog at the end of July 2020 was approximately $38 million, up approximately $2 million from the previous year-end April 30, 2020. The company's balance sheet continues to reflect the strong working capital position of approximately $39 million at July 31, 2020, and a current ratio of approximately 4.6:1. The company believes that its liquidity is adequate to meet its operating and investing needs for the next 12 months and the foreseeable future. I will turn the call back to Stan, and we look forward to your questions later.